

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following side effects was the most common Grade 3 or higher adverse event observed with capiwasertib in the Phase III CAPItello-291 trial?
 - Diarrhea
 - Hyperglycemia
 - Stomatitis
 - Rash
- Which therapy yielded the greatest reduction in the risk of disease progression or death among the overall population in the Phase III EMBER-3 trial of imlunestrant as monotherapy or combined with abemaciclib versus standard endocrine therapy for patients with ER-positive, HER2-negative advanced breast cancer pretreated with endocrine therapy?
 - Standard endocrine therapy
 - Imlunestrant monotherapy
 - Imlunestrant and abemaciclib
 - Imlunestrant monotherapy and imlunestrant with abemaciclib yielded similar benefits
- Trastuzumab deruxtecan has demonstrated robust intracranial activity in patients with HER2-positive metastatic breast cancer with ...
 - Treated or stable brain metastases
 - Untreated or active brain metastases
 - Both a and b
 - Neither a nor b
- What was the approximate reduction in the risk of disease progression or death with datopotamab deruxtecan compared to investigator's choice of chemotherapy for patients with previously treated HR-positive, HER2-negative breast cancer in the Phase III TROPION-Breast01 study?
 - 12%
 - 37%
 - 68%
- The Phase III INAVO120 study investigated the efficacy of inavolisib with palbociclib and fulvestrant for patients with HR-positive, HER2-negative locally advanced/metastatic breast cancer with which of the following mutations?
 - BRCA
 - AKT
 - ESR1
 - PIK3CA